Signatera detects molecular residual disease in bladder cancer by identifying tumor DNA fragments in the bloodstream, even when not visible on scans. The IMvigor010 trial showed that Signatera-guided ...

Results from a large clinical trial show that treatment with an immunotherapy drug may nearly double the length of time people with high-risk, muscle-invasive bladder cancer are cancer-free following ...

Can growing blood vessels within a lab-engineered graft improve bladder reconstruction for children? For more than two decades, UC Davis pediatric urologic surgeon Eric Kurzrock has been developing ...

Historic surgery, the result of years of research at Keck Medicine of USC and UCLA Health, opens the door for improved treatment of non-functioning bladders “This surgery is a historic moment in ...

FDA authorization extends perioperative pembrolizumab plus enfortumab vedotin to cystectomy-eligible muscle-invasive bladder cancer, removing the prior restriction to cisplatin-ineligible patients.